How EPT Programs Could Stem The Rise Of STD Cases

Expedited partner therapy (EPT) lets a person diagnosed with chlamydia or gonorrhea carry treatment, a prescription or the medicine itself, to their sex partner without that partner needing their own exam. At the population level, EPT could slow rising STI rates by getting more partners treated, cutting reinfection and breaking transmission chains that standard referral misses.

What expedited partner therapy (EPT) is

EPT is the practice of treating the sex partners of someone diagnosed with chlamydia or gonorrhea by giving the patient a prescription or the actual medicine to deliver to their partner, without the provider examining that partner first CDC. The aim is to make sure partners actually get treated so the index patient isn't reinfected. It's used mainly for chlamydia and gonorrhea, the two bacterial infections where a quick course of antibiotics reliably clears the infection.

It exists because the old model fails too often. Under standard "patient referral," the diagnosed person is told to ask their partner to go get tested and treated. Many partners never make that appointment, whether from no time, no insurance, no symptoms, or no desire to disclose. EPT removes the appointment barrier entirely, and your partner gets treated without their own visit, which is frequently the difference between treated and not. For the full clinical breakdown, see our expedited partner therapy guide.

How EPT works at the program level

At the level of a clinic or a public-health department, EPT interrupts transmission rather than just adding convenience. When a clinician diagnoses chlamydia or gonorrhea, they offer the patient enough treatment for their recent partners to take home. The 2021 CDC STI Treatment Guidelines state that, unless prohibited by law, providers should routinely offer EPT to patients with chlamydia when they can't ensure that all of a patient's sex partners from the previous 60 days will seek timely treatment CDC, 2021.

CDC has backed this approach for gonorrhea since 2006, originally for heterosexual partners unlikely to seek timely care CDC. The 60-day window targets the partners most likely to still be infected and most likely to bounce the infection back. Treating that pool quickly, rather than waiting for each partner to navigate the health system on their own, is what makes EPT a population tool. The recommended take-home regimen for chlamydia is azithromycin as a single oral dose or a short course of doxycycline; for gonorrhea, an oral cefixime dose, with doxycycline added if chlamydia hasn't been ruled out AAFP, 2021.

The evidence that EPT reduces reinfection and onward transmission

The case for EPT rests on real trials. CDC's 2021 evidence base draws on three U.S. clinical trials in heterosexual men and women with chlamydia or gonorrhea; all three found more partners got treated with EPT, and two reported statistically significant drops in reinfection. Pooled across U.S. trials and a meta-analysis, EPT was associated with roughly a 20% reduction in chlamydia and roughly a 50% reduction in gonorrhea at follow-up compared with standard patient referral CDC EPT guidelines.

The landmark King County, Washington randomized trial put numbers on it: index patients who got EPT had lower repeat gonorrhea (3.0% vs 11.0%) and lower repeat chlamydia (11.0% vs 13.0%) than those given standard referral NIH/PMC review citing Golden et al. 2005. Reinfection happens in roughly 10–15% of treated patients within six months, and each reinfection raises the risk of reproductive complications like pelvic inflammatory disease and infertility.

Scaling that benefit to whole communities is harder. A Washington State community-level stepped-wedge trial found the intervention was associated with about a 10% reduction in chlamydia positivity (prevalence ratio 0.89) and a similar reduction in gonorrhea incidence (rate ratio 0.91) Washington State EPT Trial. The effect is smaller than in tightly controlled patient-level studies, since real-world adoption rather than the drug is the limiting factor. ACOG has weighed the trade-offs and concluded that EPT's benefits in preventing reinfection outweigh the risks of antibiotic side effects, resistance, or a missed in-person care opportunity ACOG, 2018.

Where the evidence is thinner: MSM and syphilis

EPT isn't a fit for every situation. CDC recommends shared clinical decision-making for men who have sex with men (MSM), because data are limited on whether EPT reduces persistent or recurrent gonorrhea in this group, and these patients may carry coinfections an exam would catch. One randomized trial among sexual minority men in Lima, Peru did show benefit, with 12-month recurrent gonorrhea/chlamydia at 19.8% in the EPT arm versus 24.0% in controls IDSA, but the body of evidence is still smaller than for heterosexuals. For syphilis, there are no data supporting EPT in routine management, so partners of someone with syphilis still need their own evaluation.

Where EPT is legal: the state-by-state picture

EPT is legal in most U.S. states, but its status varies, including by which infection it can be used for, so availability depends on your local law CDC. In some places it's explicitly permitted by statute or regulation; in others it's "potentially allowable" with no law prohibiting it; in a small number it remains legally murky. The legal status can also differ between chlamydia and gonorrhea within the same state. CDC maintains a current map of where it stands, and for most patients it's available if you ask.

The barriers: legality, pharmacy, and reimbursement

Three obstacles keep EPT from reaching its potential.

• Legal uncertainty. Even where EPT isn't prohibited, some clinicians hesitate without explicit legal cover, worried about prescribing for a patient they haven't examined.
• Pharmacy friction. A take-home prescription written for an unnamed or unseen partner can be confusing at the counter, and not every pharmacist is familiar with how EPT prescriptions should be handled.
• Reimbursement gaps. The partner often isn't a patient of record, so insurance may not cover the medication, leaving the index patient to pay out of pocket, a real cost barrier even when the law allows it.

None of these is the drug's fault; they're system problems. Where states pass clear EPT laws, clinics build it into their workflow, and payers cover the partner's medication, uptake climbs. That gap between EPT's trial results and its real-world impact is what needs closing.

How scaling EPT could bend the STI curve

Chlamydia and gonorrhea spread through networks, and every untreated partner re-seeds infection back into the index patient and outward to new contacts. Treat that partner fast and you remove the node before it transmits again. Multiply the per-couple reductions seen in trials across thousands of diagnoses, and you get the community-level signal Washington State observed.

Bending the curve means three things happening together: legalizing EPT everywhere, making it the default offer at diagnosis rather than an afterthought, and solving the payment problem so the take-home medicine is actually free or cheap. EPT won't replace partner notification, testing, or in-person care for complex cases, but layered on top of those as a population strategy, it's one of the few tools with randomized evidence behind it.

EPT regimens at a glance

How to access EPT as a patient

If you've been diagnosed with chlamydia or gonorrhea, ask your clinician or pharmacist directly about EPT. It's legal in most states and helps you avoid being reinfected by an untreated partner. Tell them how many recent partners you've had and whether they're likely to get to a clinic on their own; that's the situation EPT was designed for. Your provider can give you the prescription or the medicine to pass along, plus written information for your partner about the dose, side effects, and warning signs that they need their own visit instead.

Your partner should still confirm they're not pregnant, not allergic to the antibiotic, and don't have symptoms suggesting a more serious infection, which are reasons to see a clinician rather than take the take-home dose. EPT treats your partner; it doesn't test them or you for anything else. If you haven't already, get tested for the full panel, and if you're recently exposed, check when to test after exposure so you don't test too early to be accurate.

When to see a clinician

EPT is for straightforward, recent partner treatment, not for everything. See a clinician in person if you or your partner have pelvic or testicular pain, fever, a rash, or symptoms that could mean the infection has spread or that something else is going on. Anyone who is pregnant, has a possible drug allergy, or may have syphilis or HIV needs direct evaluation. And if your symptoms don't clear after treatment, get re-examined rather than re-treated by proxy.

Keep exploring on EasySTD: when to re-test, telling recent partners and Chlamydia testing.